Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 54 |
| Active Pipeline (Recruiting Now) | 33 (25) |
| Completed vs Stopped Early | 12 / 9 (16.7%) |
| Median Closed Actual Enrollment | 28 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Rutgers Cancer Institute of New Jersey | New Brunswick, NJ | 15 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | Phase II | RECRUITING |
| NCT05559164 | Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | Phase II | RECRUITING |
| NCT05358548 | ATATcH Alternating Treatment Plans for Advanced Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Rutgers, The State University of New Jersey Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.